Methods
Using a transplantable murine model derived from E2A-PBX1 transgenic mice we studied the impact of ALL progression on T cell function in vivo, and also the implication of the blockage of the immune checkpoints.
Results
Vaccination protects mice against E2a-PBX1.3 and requires T cells and NK cells. However, therapeutic vaccination after ALL challenge is ineffective even when administered early at a low disease burden. Adoptive transfer of primed T cells from immunized donors can completely eradicate the leukemia blast. Unfortunately, T cells from leukemic mice fail to protect against E2a-PBX1.3 following adoptive transfer. T cells from leukemic mice express the programmed death receptor 1 (PD1) with progressive accumulation of additional markers of T cell dysfunction including LAG-3, and Tim-3. Furthermore, the expression of PD-1 on the T cell from the tumor bearing mice is not solely dependent on the TCR signaling. T cells from the bone marrow of children with ALL also contained large numbers of PD1+ T cells. Blockade of PD1 or its ligand, PDL1, were ineffective at preventing E2aPBX1.3 progression. Finally, expression of a chimeric antigen receptor targeting CD19 in T cells from leukemic mice fails to restore function while the T cells from naïve mice can completely cure the receipts.
Conclusions
These findings have important implications for the optimization of immunotherapy for ALL including adoptive cell therapies utilizing CAR-expressing T cells when generated from donors with leukemia.
